Moneycontrol Bureau
Suven Life Science Monday said it has got product patent for its new chemical entity, 5-HT compounds used to treat neurodegenerative diseases like Parkinson and Schizophrenia from Europe, New Zealand, Australia and Korea.
The patents are valid till 2025, the company said in a press release Thursday.
With these new patents, Suven has a total of eight granted patents from Europe, 10 from New Zealand, nine from Australia and three from Korea, the company said.
"The patents to Suven for our pipeline of melecules in CNS arena that are being developed for cognitive disorders has an estimated USD 30 billion market potential globally," said Venkat Jasti, chief financial officer of Suven.
At 11:25 hrs, shares of Suven Life Science were trading at Rs 21.05, up 5% on the Bombay Stock Exchange.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
